A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.
A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.
